Early-Onset Alzheimer's Disease

What Early-Onset Alzheimer's Disease is

Early-Onset Alzheimer's Disease (sometimes called Young-Onset Alzheimer's Disease) is Alzheimer's Disease in which symptoms begin before age 65. It shares the underlying amyloid and tau pathology of late-onset disease, but the presentation and course often differ. Around 5 per cent of all Alzheimer's Disease falls into the early-onset category, equating to roughly 40,000 people in the UK.

How it presents

Late-onset Alzheimer's Disease is dominated by short-term memory loss. Early-Onset Alzheimer's Disease more often presents with atypical features:

• Visuospatial difficulties (the Posterior Cortical Atrophy variant);
• Language difficulty (the Logopenic Variant Primary Progressive Aphasia);
• Executive and behavioural change (the dysexecutive or frontal variant);
• Memory loss in a more classical pattern, in around half of cases.

The atypical presentations explain why diagnosis is often delayed: the symptoms do not match the typical "memory loss" picture, and clinicians may not initially consider Alzheimer's Disease in a person in their fifties.

Genetics

A small minority (around 1 to 2 per cent of all Alzheimer's Disease) is caused by single-gene mutations: PSEN1, PSEN2 or APP. These are inherited in an autosomal dominant pattern, meaning a child of an affected parent has a 50 per cent risk of inheriting the mutation. Where a strong family history of early-onset Alzheimer's is present (multiple relatives with disease onset before age 65), genetic counselling is recommended. Genetic testing is available through NHS regional genetics services and is a complex decision that benefits from specialist input.

The majority of Early-Onset Alzheimer's Disease is sporadic, with risk influenced by the same factors as late-onset disease (vascular risk factors, APOE4 genotype, head injury, lifestyle).

How it is diagnosed

Standard memory clinic assessment applies (history, ACE-III, blood tests, ECG, Magnetic Resonance Imaging), with a lower threshold for advanced investigations:

• Formal neuropsychometric assessment to characterise atypical patterns;
• FDG-PET to support diagnosis in atypical presentations;
• Lumbar Puncture for CSF biomarkers (amyloid and tau), increasingly relevant for eligibility for clinical trials and future anti-amyloid therapies;
• Genetic counselling and, where appropriate, testing if family history is strong.

Treatment

The standard Alzheimer's Disease treatments apply: Cholinesterase Inhibitors for mild to moderate disease, Memantine for moderate to severe disease. People with Early-Onset Alzheimer's Disease are often eligible for clinical trials, including the new anti-amyloid antibody therapies (currently not recommended for routine NHS use; see Lecanemab and Donanemab).

Practical and social differences

Early-Onset Alzheimer's Disease typically affects people who are still working, with dependent children at home, and with substantial financial commitments. The practical priorities differ from late-onset disease:

• Work: Equality Act 2010 protections, reasonable adjustments, and decisions about reduced hours, role change or retirement;
• Income protection: critical illness cover, income protection insurance and pension considerations;
• Family: telling adolescent or young adult children, managing the family role; see children and grandchildren;
• Driving: implications for both private licence and any commercial entitlement;
• Legal: Lasting Power of Attorney while capacity is intact, and an up-to-date will.

Support tailored to younger adults

National charities run specific services for younger people with dementia, recognising that conventional services (often weekday daytime, with an older cohort) may not suit. Examples include Young Dementia Network, Alzheimer's Society young-onset services, and Rare Dementia Support for atypical variants. Local services vary.

Where The Dementia Service fits in

Early-Onset Alzheimer's Disease often benefits from prompt structured assessment, particularly given the higher likelihood of atypical presentations. The Dementia Service can deliver a comprehensive ICD-11 aligned assessment with onward investigation including neuropsychology, FDG-PET and (where indicated) genetic counselling referral.